Gene Expression Profiling for the Diagnosis and Prognosis of Acute Myeloid Leukaemia
Overview
Authors
Affiliations
Acute myeloid leukaemia (AML) is a heterogeneous disease covering a range of morphological lineages and differentiation stages, but also has number of recurrent chromosomal abnormalities and mutations associated with prognosis. Because of the defined molecular and cytogenetic features, AML has been a focus of gene expression profiling studies and identified differentially expressed genes in the different diagnostic and cytogenetic sub-groups. These studies have lead to the development of expression based classifications and diagnostic chips with further studies aiding prognosis and therapeutic choices.
Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma.
Komohara Y, Noyori O, Saito Y, Takeya H, Baghdadi M, Kitagawa F J Clin Exp Hematop. 2018; 58(4):152-160.
PMID: 30541986 PMC: 6407477. DOI: 10.3960/jslrt.18034.
El-Serafi I, Abedi-Valugerdi M, Potacova Z, Afsharian P, Mattsson J, Moshfegh A PLoS One. 2014; 9(1):e86619.
PMID: 24466173 PMC: 3899295. DOI: 10.1371/journal.pone.0086619.
Kornblau S, Minden M, Rosen D, Putta S, Cohen A, Covey T Clin Cancer Res. 2010; 16(14):3721-33.
PMID: 20525753 PMC: 3385931. DOI: 10.1158/1078-0432.CCR-10-0093.
The role of molecular tests in acute myelogenous leukemia treatment decisions.
Motyckova G, Stone R Curr Hematol Malig Rep. 2010; 5(2):109-17.
PMID: 20425404 DOI: 10.1007/s11899-010-0049-7.
Bogunovic D, ONeill D, Belitskaya-Levy I, Vacic V, Yu Y, Adams S Proc Natl Acad Sci U S A. 2009; 106(48):20429-34.
PMID: 19915147 PMC: 2787158. DOI: 10.1073/pnas.0905139106.